Suppr超能文献

传统草药作为癌症化学预防的天然产物基质:转化药理学视角(范围综述)。

Traditional medicine herbs as natural product matrices in cancer chemoprevention: A trans pharmacological perspective (scoping review).

机构信息

Department of Pharmacognosy, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Department of Agadatantra, Ayurveda College, Coimbatore, India.

出版信息

Phytother Res. 2023 Apr;37(4):1539-1573. doi: 10.1002/ptr.7747. Epub 2023 Feb 14.

Abstract

Emerging evidence on molecular biology related to tumors, inflammation, and immunity, highlights their architectural commonality shifting cancer treatment paradigms toward more economical prevention than treatment. Statistical surveys reveal exponentially growing herbal drug supplementation in cancer worldwide as vast pre-clinical and clinical data unravel their multi-mechanistic pharmacology. The integrative oncological approach calls for more "holistic" principles to be amalgamated into cancer care. New cancer drug development from herbs need not be limited by the archetypal 'RCT-Standardization' bottlenecks. Based on comprehensive literature scoping as per Prisma-ScR guidelines, we herein concurrently reviewed evidence-based research reports of selected Indian Traditional Medicine (ITM) herbs of anticancer repute in parallel with their holistic therapeutics; a rationalistic exploration of ITM's scientific genre. Their synergy effect on cancer revisited using a trans-pharmacological approach validates ITM's seemingly simplistic health/disease equation model, showing a fresh new avenue for re-purposing whole herbal drug complexes in cancer management. Herbal drugs as per ITM are natural matrices whose dynamics of interaction in the etiopathology of cancer are conceptually and mechanistically integrative. Lateral perspective to the same as laid out in this review holds the key to their effectual development as more tangible cancer chemopreventives/new drug targets/leads if not as new pharmacological tools.

摘要

新兴的与肿瘤、炎症和免疫相关的分子生物学证据强调了它们在结构上的共性,将癌症治疗模式从治疗转向更经济的预防。统计调查显示,全球范围内癌症的草药药物补充呈指数级增长,大量的临床前和临床数据揭示了它们的多机制药理学。综合肿瘤学方法呼吁将更多的“整体”原则纳入癌症治疗中。草药新抗癌药物的开发不一定受到典型的“RCT-标准化”瓶颈的限制。根据 Prisma-ScR 指南进行的全面文献范围界定,我们同时审查了具有抗癌声誉的选定印度传统医学 (ITM) 草药的循证研究报告及其整体治疗方法;这是对 ITM 科学类型的理性探索。使用跨药理学方法重新审视它们对癌症的协同作用,验证了 ITM 看似简单的健康/疾病方程模型,为重新利用整个草药药物复合物治疗癌症提供了新的途径。根据 ITM,草药是天然基质,其在癌症发病机制中的相互作用动态在概念上和机制上是综合的。从侧面来看,正如本综述所阐述的那样,这是有效开发它们的关键,如果不能作为新的药理学工具,那么它们可以作为更切实可行的癌症化学预防剂/新药靶点/先导化合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验